Tokyo - Delayed Quote JPY

StemCell Institute Inc. (7096.T)

1,095.00
-22.00
(-1.97%)
At close: 3:30:00 PM GMT+9
Loading Chart for 7096.T
  • Previous Close 1,117.00
  • Open 1,114.00
  • Bid 1,088.00 x --
  • Ask 1,097.00 x --
  • Day's Range 1,085.00 - 1,117.00
  • 52 Week Range 1,085.00 - 1,923.00
  • Volume 53,700
  • Avg. Volume 29,701
  • Market Cap (intraday) 11.138B
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) 26.49
  • EPS (TTM) 41.33
  • Earnings Date May 13, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Sep 27, 2024
  • 1y Target Est --

StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.

www.stemcell.co.jp

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 7096.T

View More

Performance Overview: 7096.T

Trailing total returns as of 6/3/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

7096.T
15.05%
Nikkei 225 (^N225)
6.14%

1-Year Return

7096.T
33.35%
Nikkei 225 (^N225)
3.79%

3-Year Return

7096.T
48.41%
Nikkei 225 (^N225)
34.89%

5-Year Return

7096.T
54.66%
Nikkei 225 (^N225)
65.59%

Compare To: 7096.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7096.T

View More

Valuation Measures

Annual
As of 6/2/2025
  • Market Cap

    11.36B

  • Enterprise Value

    8.52B

  • Trailing P/E

    27.05

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.33

  • Price/Book (mrq)

    3.96

  • Enterprise Value/Revenue

    3.23

  • Enterprise Value/EBITDA

    14.63

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.37%

  • Return on Assets (ttm)

    3.73%

  • Return on Equity (ttm)

    14.48%

  • Revenue (ttm)

    2.68B

  • Net Income Avi to Common (ttm)

    385M

  • Diluted EPS (ttm)

    41.33

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.2B

  • Total Debt/Equity (mrq)

    19.67%

  • Levered Free Cash Flow (ttm)

    7.25M

Research Analysis: 7096.T

View More

Company Insights: 7096.T

Research Reports: 7096.T

View More

People Also Watch